Asia Pacific Radiopharmaceutical Theranostics Market

The Asia Pacific radiopharmaceutical theranostics market was valued at US$ 337.53 million in 2022 and is expected to reach US$ 667.40 million by 2028; it is estimated to register a CAGR of 12.0% from 2022 to 2028.

Radiopharmaceutical Theranostics in Nuclear Medicine

Theranostics in nuclear medicine gathers researchers’ interest through molecular imaging and personalized medicine. This is achieved through assistance in the management of various diseases, improves patient selection process, predicts drug response and toxicity, determines prognosis, and helps avoid futile and costly/expensive examinations and treatments. The theranostic approach to nuclear medicine involves a combination of diagnostic imaging and therapy based on a radioactive drug; its primary focus is the diagnosis, while the secondary focus is the treatment of a tumor site. Radioiodine was the first theranostic radiopharmaceutical used in treating and imaging thyroid diseases. In radioiodine therapy, the radioisotope iodine-131 is a gamma and beta emitter, and the sodium-iodide symporter can directly mediate the gamma emitter to thyroid cells. Further, gamma and positron emitters (β+) are used in nuclear imaging. Gamma emitters such as technetium-99m or iodine-123 are used in SPECT imaging, whereas the use of gallium-68 and fluorine-18 in PET imaging can provide better resolution. Therefore, theranostics-based nuclear-targeted therapies are emerging as a useful tool for treating patients suffering from advanced neuroendocrine and gastroenteropancreatic tumors such as neuroblastomas.

Asia Pacific Radiopharmaceutical Theranostics Market Overview

The Asia Pacific radiopharmaceutical theranostics market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. China held the largest share of the market in 2021, and India is expected to exhibit a significant growth pace in the market during the forecast period. The market growth in these countries is attributed to the rising chronic disease prevalence and favorable reimbursement policies. Moreover, expansion and product launch strategies implemented by market players are expected to contribute to the growth of the radiopharmaceutical theranostics market in the region.

Asia Pacific Radiopharmaceutical Theranostics Market Revenue and Forecast to 2028 (US$ Million)

Asia Pacific Radiopharmaceutical Theranostics Strategic Insights

Strategic insights for the Asia Pacific Radiopharmaceutical Theranostics provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Asia Pacific Radiopharmaceutical Theranostics Report Scope

Asia Pacific Radiopharmaceutical Theranostics Regional Insights

The geographic scope of the Asia Pacific Radiopharmaceutical Theranostics refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

Asia Pacific Radiopharmaceutical Theranostics Market Segmentation

The Asia Pacific radiopharmaceutical theranostics market is segmented into product type, Radioisotope, source, application, indication, end user, and country. Based on product type, the Asia Pacific radiopharmaceutical theranostics market is segmented into alpha emitters, beta emitters, and positron emission tomography (PET) tracers. The PET tracers segment held the largest market share in 2022.

Based on Radioisotope, the Asia Pacific radiopharmaceutical theranostics market is segmented into technetium-99, gallium-68, iodine-131, iodine-123, Fluorine-18 (18F), Yttrium 90 (Y-90), Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, and others. The Lutetium (Lu) 177 segment held the largest market share in 2022.

Based on source, the Asia Pacific radiopharmaceutical theranostics market is bifurcated into nuclear reactors and cyclotrons. The cyclotrons segment held a larger market share in 2022.

Based on application, the Asia Pacific radiopharmaceutical theranostics market is bifurcated into targeted therapeutic (Rx) and Companion Diagnostic (CDx). The targeted therapeutic (Rx) segment held a larger market share in 2022.

Based on indication, the Asia Pacific radiopharmaceutical theranostics market is segmented into oncology, cardiology, neurology, and others. The oncology segment held the largest market share in 2022.

Based on end user, the Asia Pacific radiopharmaceutical theranostics market is segmented into hospitals, diagnostic imaging centers, academic and research institutes, and others. The oncology segment held the largest market share in 2022.

Based on country, the Asia Pacific radiopharmaceutical theranostics market is segmented into China, India, Japan, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific radiopharmaceutical theranostics market share in 2022.

Bayer AG, GE Healthcare Technologies Inc., Curium, Telix Pharmaceuticals Ltd., and Cardinal Health Inc. are among the leading companies operating in the Asia Pacific radiopharmaceutical theranostics market.